Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

A double‐blind, randomized, placebo‐controlled dose‐ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome

Open access
Bardhan, Bodemar, Geldof, Schütz, Heath, Mills, Jacques · 2000 · Alimentary Pharmacology & Therapeutics

Abstract

Background: Irritable bowel syndrome is a common gastrointestinal disorder characterized by abdominal pain and discomfort and altered bowel habit. Antagonism at the 5‐HT 3 receptor may be of benefit in the treatment of irritable bowel syndrome. Aims: To evaluate the effect of 12 weeks of treatment with alosetron, a 5‐HT 3 receptor antagonist at doses of 0.1 mg b.d., 0.5 mg b.d. and 2 mg b.d. in irritable bowel syndrome patients. Methods: A double‐blind, placebo‐controlled, parallel‐group study with a 2‐week screening and a 12‐week treatment period was conducted. A total of 462 patients (335 female) recorded details of the severity of their abdominal pain, and bowel function daily on a diary card throughout the study. At monthly clinic visits patients recorded the severity of their abdominal pain/discomfort and diarrhoea on a visual analogue scale. Results: In the total population and in the female subpopulation (but not in males) alosetron 2 mg b.d. significantly increased the proportion of pain‐free days and decreased the visual analogue scale score for diarrhoea compared with placebo. Alosetron at doses of 0.5 mg b.d. and 2 mg b.d. led to a significant hardening of stool, and a reduction in stool frequency in the total population. Conclusion: Alosetron at a dose of 2 mg b.d. is an effective treatment for female patients with irritable bowel syndrome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2000.00684.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 161

Metadata

Authors
Bardhan, Bodemar, Geldof, Schütz, Heath, Mills, & Jacques
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2000-01
Volume
14
Issue
1
Pages
23-34
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2008019573
Cited by
161
References
4
FWCI
15.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A double‐blind, randomized, placebo‐controlled dose‐ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. https://app.cochat.ai/papers/10.1046/j.1365-2036.2000.00684.x
The paper
Bardhan, Bodemar, Geldof, Schütz, Heath, Mills, & Jacques. (2000). A double‐blind, randomized, placebo‐controlled dose‐ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2000.00684.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.